Clinical trials: Metastatic Renal Cancer
Urothelial Carcinoma, Ureteral Neoplasms
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Background: Urothelial cancer (tumors of the bladder, urethra, ureter, or renal pelvis) often responds initially to standard chemotherapy treatments, but frequently recurs and can often spread to other parts of the body.
- Conditions
- Urothelial Carcinoma, Ureteral Neoplasms, Ureter Cancer, Neoplasm, Ureteral
- Trial name
- NCT01328574
- Testing
- TRC105
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Cancer Metastatic
Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma
The goal of this multicenter observational study is to elucidate the clinical and immunological characteristics of the abscopal effect in patients with metastatic renal cell carcinoma (mRCC) receiving immune checkpoint inhibitors…
- Trial name
- AURICRE (NCT07240610)
- Where
- Japan
- Volunteers
- 145 people
- Sponsor
- Zhe Chen
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
Phase II trial to study the effectiveness of combining oblimersen with interferon alfa in treating patients who have metastatic renal cell (kidney) cancer. Interferon alfa may interfere with the growth of tumor cells.
- Trial name
- NCT00059813
- Testing
- recombinant interferon alfa, oblimersen sodium, pharmacological study
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Renal Cell Cancer
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person.
- Conditions
- Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma
- Trial name
- NCT02830724
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
This is a Phase II, non-randomized, open-label, single-arm study in patients with metastatic renal cell carcinoma who have received one prior targeted therapy with either sunitinib or bevacizumab.
- Trial name
- NCT00731211
- Testing
- Pazopanib
- Where
- 17 sites in United States
- Volunteers
- 57 people
- Sponsor
- SCRI Development Innovations, LLC
Renal Cell Carcinoma
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Immunotherapy with checkpoint inhibitors that target PD-1 and CTLA-4 have shown activity in mRCC. However, the optimal schedule of the combination therapy has yet to be defined.
- Trial name
- NCT03297593
- Testing
- nivolumab, ipilimumab
- Where
- 14 sites in Switzerland
- Volunteers
- 74 people
- Sponsor
- Swiss Cancer Institute
Cancer, Immunotherapy
Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.
This clinical trial aims to evaluate whether a ketogenic diet (KD), when combined with immunotherapy, can improve immune function and treatment outcomes in patients with advanced melanoma, cutaneous squamous cell carcinoma…
- Conditions
- Cancer, Immunotherapy, Ketogenic Diet
- Trial name
- NCT06896552
- Testing
- Ketogenic diet
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Carcinoma, Renal Cell
Sorafenib in Elderly mRCC
This prospective, single arm, multi-center pilot study includes 120 mRCC patients over 65 years, no prior systemic treatment, determined to be candidates for systemic therapy by the investigator.
- Trial name
- NCT01728948
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Bayer
Liver and Kidney Tumours
Thermal Ablation in Larger Liver and Kidney Tumours
This is a clinical research study designed to determine the safety and efficacy of the application of a unique interstitial radio frequency thermal therapy for the treatment of large tumours in the kidney or liver.
- Trial name
- NCT01720706
- Testing
- RFA Loosely wound thermal coil
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Carcinoma, Renal Cell
Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.
- Trial name
- MRCC RCC (NCT00706706)
- Testing
- Sunitinib Malate (SU011248)
- Where
- 11 sites in China
- Volunteers
- 105 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
Sunitinib in Metastatic Renal Cancer
Sunitinib is the registered treatment for first-line therapy of metastatic clear-cell carcinoma of the kidney.Data from the Expanded Access Study have shown activity also in non-clear cell renal cancer (NCCRC).
- Trial name
- NCT01034878
- Testing
- Sunitinib
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Istituto Clinico Humanitas
Kidney Cancer
Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00077129
- Testing
- carboplatin, paclitaxel
- Where
- 35 sites in United States
- Volunteers
- 22 people
- Sponsor
- Eastern Cooperative Oncology Group
Advanced or Metastatic Renal Cell Carcinoma
A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan
The purpose of the observational study is to evaluate the safety and effectiveness of combination therapy with nivolumab and ipilimumab in Japanese participants with advanced or metastatic renal cell carcinoma (aRCC) in the…
- Trial name
- NCT04043975
- Where
- Japan
- Volunteers
- 286 people
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma, Cardiotoxicity
A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)
While sunitinib can be very helpful to treat kidney cancer, these medications can also cause side effects, including heart damage.
- Conditions
- Renal Cell Carcinoma, Cardiotoxicity, Heart Failure, Hypertension
- Trial name
- SUPER (NCT01014065)
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- AHS Cancer Control Alberta
Renal Cell Carcinoma
Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma
The purpose of this study is to see if researchers can detect circulating tumor cells (CTC) and circulating endothelial cells (CEC) in the blood.
- Trial name
- NCT01173445
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Kansas
Diarrhea Caused by Drug (Disorder), Renal Cell Cancer
Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors
Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with metastatic renal cell carcinoma, and are commonly used as first-line option for this condition, but their use is encumbered by side effects, mainly…
- Trial name
- NCT04040712
- Testing
- Donor FMT
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Catholic University of the Sacred Heart
Kidney Cancer
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00087022
- Testing
- girentuximab
- Where
- 56 sites in United States, Argentina and 2 more
- Volunteers
- 864 people
- Sponsor
- Heidelberg Pharma AG
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
Objectives: Primary: Safety and tolerability of therapy with daratumumab in a cohort of patients with metastatic renal cell carcinoma and a cohort of patients with muscle invasive bladder cancer. Secondary: 1A.
- Conditions
- Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma
- Trial name
- NCT03473730
- Testing
- Biopsy, Daratumumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Renal Cell Carcinoma
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
This study is being done with patients with advanced kidney cancer (also called renal cell carcinoma or RCC). This is a research study involving the use of the drug Nivolumab (also known as Opdivo®).
- Trial name
- NCT03126331
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Kidney Cancer, Renal Cell Carcinoma Metastatic
Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
BACKGROUND: For synchronous metastatic renal cell carcinoma (RCC), surgical resection of the primary tumor in the presence of distant metastases has been the standard of therapy for select patients followed by systemic therapy.
- Conditions
- Kidney Cancer, Renal Cell Carcinoma Metastatic, Synchronous Neoplasm
- Trial name
- NORDIC-SUN (NCT03977571)
- Testing
- Cytoreductive nephrectomy, Tissue sampling
- Where
- 11 sites in Denmark, Finland and 2 more
- Volunteers
- 400 people
- Sponsor
- Niels Fristrup
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.